RSS: Dartmouth Cancer Center Grand Rounds 2024

Session Date: December 17, 2024 ● 12:00 PM - 1:00 PM

Title: Dartmouth Cancer Center Grand Rounds 2024 - 12/17/2024 Clinical Management of Metastatic Disease to Bone (E.

Henderson, T. Delaney, L. Evans, C. Hayes, and K. Hixon)

Session Speaker:

Eric R Henderson, MD

MD

Dartmouth Hitchcock Medical Center

Linton Evans, MD

Dartmouth Hitchcock Medical Center

Christi Hayes, MD

Dartmouth Hitchcock

Thomas F DeLaney, MD Physician Dartmouth Hitchcock Medical Center

Katherine Hixon, PhD Assistant Professor Dartmouth College

Accreditation:

In support of improving patient care, Dartmouth Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Medical Association (AMA)

Dartmouth Health designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: All other learners may claim CME-designated participation credit. Consult your professional licensing board regarding the applicability and acceptance of CME-designated participation credit for programs certified for credit by organizations accredited by Joint Accreditation for Interprofessional Education.

Learning Objectives:

At the conclusion of this learning activity, participants will be able to:

1 Discuss at least three evidence-based changes in the care and treatment of patients with a cancer diagnosis.

Dartmouth Health adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including planners, faculty, authors, or others are required to disclose all financial relationships with ineligible companies[^]. All relevant financial relationships have been mitigated prior to the commencement of the activity.

^Ineligible Company is any entity whose primary business purpose is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Eric R Henderson, MD	Faculty	Paid consultant-Stryker (Any division) (Relationship has ended) - 09/29/2024
Linton Evans, MD	Faculty	Consulting Fee-Zeiss - 09/30/2024
Christi Hayes, MD	Faculty	Nothing to disclose - 11/11/2024
Thomas F DeLaney, MD	Faculty	Consulting Fee-Teladoc Health Inc Royalties or Patent Beneficiary- Springer Verlag Publishing - 10/23/2024
Charles R Thomas, MD	Course Director	Nothing to disclose - 09/22/2024
Robert W Gerlach, MPA	Other Planning Committee Member	Nothing to disclose - 09/20/2024
Sharon Williamson, MBA	Activity Coordinator	Nothing to disclose - 02/23/2024
Oluwatoyin A Asojo, PhD	Other Planning Committee Member	Nothing to disclose - 09/20/2024
Steven N Fiering, PhD	Other Planning Committee Member	Nothing to disclose - 09/20/2024
Katherine Hixon, PhD	Faculty	Nothing to disclose - 12/03/2024

Mobile Text-In Code for this Session Only

<Code>

Code Expires in 48 Hours

Text Requests for Credit to this Number: (833-884-3375)

Need help? clpd.support@hitchcock.org

Create New Account dh.cloud-cme.com